Assurant, Inc. (AIZ) At $90.03 Forms Bottom; Last Week Neos Therapeutics, Inc. (NEOS) Coverage

Among 7 analysts covering Neos Therapeutics (NASDAQ:NEOS), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Neos Therapeutics had 22 analyst reports since August 17, 2015 according to SRatingsIntel. The stock has “Buy” rating by BMO Capital Markets on Friday, September 15. On Monday, August 17 the stock rating was initiated by JMP Securities with “Market Outperform”. The rating was maintained by RBC Capital Markets on Tuesday, August 8 with “Buy”. The rating was maintained by BMO Capital Markets on Tuesday, June 20 with “Buy”. The firm has “Outperform” rating given on Monday, August 17 by BMO Capital Markets. BMO Capital Markets maintained the shares of NEOS in report on Thursday, October 26 with “Buy” rating. Wells Fargo initiated the shares of NEOS in report on Friday, February 19 with “Outperform” rating. The firm has “Outperform” rating by RBC Capital Markets given on Monday, August 17. On Wednesday, June 29 the stock rating was initiated by BMO Capital Markets with “Outperform”. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. See Neos Therapeutics, Inc. (NASDAQ:NEOS) latest ratings:

31/01/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Downgrade
08/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0 Maintain
26/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $14.0 Maintain
26/10/2017 Broker: Cowen & Co Rating: Buy
18/10/2017 Broker: Wells Fargo Rating: Buy New Target: $14.0
18/09/2017 Broker: JMP Securities Rating: Buy New Target: $30.0
15/09/2017 Broker: BMO Capital Markets Rating: Buy New Target: $14.0 Maintain
14/09/2017 Broker: RBC Capital Markets Rating: Buy New Target: $12.0 Maintain

Assurant, Inc. (AIZ) formed multiple bottom with $86.43 target or 4.00% below today’s $90.03 share price. Assurant, Inc. (AIZ) has $4.72B valuation. The stock increased 1.55% or $1.37 during the last trading session, reaching $90.03. About 285,973 shares traded. Assurant, Inc. (NYSE:AIZ) has risen 14.19% since March 6, 2017 and is uptrending. It has underperformed by 2.51% the S&P500.

Among 8 analysts covering Assurant (NYSE:AIZ), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Assurant has $127 highest and $70 lowest target. $95.83’s average target is 6.44% above currents $90.03 stock price. Assurant had 11 analyst reports since July 30, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Neutral” rating in Wednesday, October 21 report. The stock has “Underperform” rating by Bank of America on Monday, January 9. The firm has “Buy” rating given on Monday, August 3 by Bank of America. The stock of Assurant, Inc. (NYSE:AIZ) earned “Buy” rating by SunTrust on Wednesday, October 11. The rating was downgraded by Bank of America on Thursday, October 20 to “Neutral”. SunTrust upgraded the stock to “Buy” rating in Thursday, July 30 report. The stock of Assurant, Inc. (NYSE:AIZ) has “Hold” rating given on Friday, August 14 by Jefferies. Credit Suisse initiated Assurant, Inc. (NYSE:AIZ) on Friday, October 7 with “Neutral” rating.

Analysts await Assurant, Inc. (NYSE:AIZ) to report earnings on May, 1. They expect $1.92 earnings per share, up 2.67% or $0.05 from last year’s $1.87 per share. AIZ’s profit will be $100.75M for 11.72 P/E if the $1.92 EPS becomes a reality. After $1.84 actual earnings per share reported by Assurant, Inc. for the previous quarter, Wall Street now forecasts 4.35% EPS growth.

Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.12, from 1.01 in 2017Q2. It dropped, as 20 investors sold Assurant, Inc. shares while 122 reduced holdings. 48 funds opened positions while 96 raised stakes. 46.94 million shares or 1.23% less from 47.53 million shares in 2017Q2 were reported. Nomura Asset Management Com owns 7,699 shares. First Limited Partnership stated it has 393,916 shares or 0.1% of all its holdings. Bank & Trust Of Nova Scotia Trust invested in 0% or 14 shares. Hancock Holdg holds 9,600 shares or 0.04% of its portfolio. Rampart Inv Mngmt Limited Liability Co holds 0.02% or 657 shares in its portfolio. 185,700 are owned by Uss Investment Mgmt. Jacobs Levy Equity Management holds 0.38% or 204,916 shares. Ontario – Canada-based Td Asset Management has invested 0.01% in Assurant, Inc. (NYSE:AIZ). Acadian Asset Management Lc stated it has 0% in Assurant, Inc. (NYSE:AIZ). Massachusetts-based Cadence Capital Management has invested 0.1% in Assurant, Inc. (NYSE:AIZ). Commonwealth Fincl Bank Of invested in 13,204 shares. 121,561 were accumulated by Sector Pension Invest Board. Northwestern Mutual Wealth Mngmt Company invested 0% of its portfolio in Assurant, Inc. (NYSE:AIZ). Credit Suisse Ag holds 85,708 shares or 0.01% of its portfolio. One Association reported 17,632 shares.

The stock increased 0.30% or $0.025 during the last trading session, reaching $8.425. About 83,083 shares traded. Neos Therapeutics, Inc. (NASDAQ:NEOS) has risen 9.07% since March 6, 2017 and is uptrending. It has underperformed by 7.63% the S&P500.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $244.30 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.